CMV Retinitis in HIV: Diagnosis and Treatment
In an HIV patient with CD4 count below 50 cells/µL presenting with visual disturbances, CMV retinitis is diagnosed clinically through dilated funduscopic examination by an ophthalmologist, and should be treated immediately with oral valganciclovir or IV ganciclovir while initiating antiretroviral therapy (ART). 1
Diagnosis
Clinical Recognition
CMV retinitis diagnosis is primarily clinical, based on characteristic ophthalmoscopic findings through dilated pupil examination 1. The pathognomonic appearance includes:
- Fluffy yellow-white retinal lesions with or without intraretinal hemorrhage
- Minimal vitreous inflammation (unless immune recovery has begun)
- Blood vessel sheathing near lesions
- "Brushfire pattern" with granular white leading edge advancing before atrophic gliotic scar 1
Screening Protocol
All HIV patients with CD4 counts <50 cells/µL require dilated funduscopic examinations every 6-12 months to detect asymptomatic disease 2. This is critical because 25% of CMV retinitis cases are discovered on routine screening before symptoms develop 3.
Symptom Patterns by Location
- Peripheral lesions: May be asymptomatic, or present with floaters, scotomata, or peripheral visual field defects
- Central lesions (macula or optic nerve involvement): Decreased visual acuity or central field defects 1
Laboratory Confirmation
While diagnosis is clinical, aqueous humor PCR for CMV-DNA can confirm diagnosis when uncertainty exists 4, 5. CMV viremia detected by PCR or antigen assays supports the diagnosis but can occur without end-organ disease 1. Serum CMV antibodies are not diagnostically useful 1.
Critical Pitfall
Coinfections may obscure diagnosis—particularly syphilitic uveitis, which can mimic CMV retinitis 4. In newly diagnosed advanced HIV, screen broadly for concurrent infections including syphilis, hepatitis B, tuberculosis, and other opportunistic infections 4.
Treatment
Immediate Sight-Threatening Lesions (Adjacent to Optic Nerve or Fovea)
Preferred approach: Ganciclovir intraocular implant PLUS oral valganciclovir 1. This combination is superior to IV ganciclovir alone for preventing relapse (AI evidence) 1. Some ophthalmologists recommend immediate intravitreous ganciclovir injection at diagnosis to achieve high local drug concentration until the implant can be placed 1.
Small Peripheral Lesions
Oral valganciclovir alone may be adequate 1. However, even small peripheral lesions warrant systemic anti-CMV therapy because:
- ART takes 3-6 months to induce sufficient immune recovery
- Larger CMV lesions increase risk of complications (immune recovery retinitis, retinal detachment)
- Anti-CMV therapy decreases mortality in immunocompromised patients with CMV retinitis 1
Treatment Options (All AI Evidence)
The following are all effective 1:
- Oral valganciclovir
- IV ganciclovir
- IV ganciclovir followed by oral valganciclovir
- IV foscarnet
- IV cidofovir
- Ganciclovir intraocular implant coupled with valganciclovir
Systemic therapy is preferred over local therapy alone because it protects the contralateral eye and other organ systems 1.
Antiretroviral Therapy
Initiate ART promptly in all patients with CMV retinitis 1. No data suggest ART worsens retinitis outcomes, and immune recovery is essential for long-term disease control (BIII evidence) 1.
Treatment Duration
- Induction phase: Continue until immune recovery occurs
- Maintenance therapy: Required until sustained CD4 count >100 cells/µL for 3-6 months 1
- Discontinuation criteria: CD4 count >100 cells/µL sustained for 3-6 months on ART (BII evidence) 1
- Reinstitution: If CD4 count drops to <100 cells/µL 1
Monitoring Requirements
Ongoing ophthalmologic follow-up is mandatory regardless of whether anti-CMV therapy continues, as relapse can occur even at CD4 counts as high as 1,250 cells/µL 1. Optimal monitoring is every 3 months after discontinuing maintenance therapy 1.
Treatment Timing Impact
Visual outcomes depend critically on treatment timing: 94.1% of eyes treated within 3 months of symptom onset showed visual improvement, compared to only 42.9% treated after 3 months 3. Without treatment, retinitis invariably progresses within 10-21 days 1.
Complications to Anticipate
- Retinal detachment: 13.1% of cases 3
- Immune recovery uveitis: 12.1% of cases 3
- Complicated cataract: 20.5% of cases 3
- Contralateral eye involvement: Two-thirds present with unilateral disease, but without treatment or immune recovery, most develop bilateral disease 1